Future Price to Earnings: Syros Pharmaceuticals (SYRS)
The market for targeted gene regulation in leukemia is highly promising due to a lack of alternatives. The forward P/E valuation trend for Syros Pharmaceuticals (SYRS) on the GURU.Markets summary chart, where the parameter value equals 0.00, is based on a unique cancer cell reprogramming platform. The Syros Pharmaceuticals business is non-cyclical, although it remains sensitive to the cost of debt when seeking liquidity.
Financial and market metric breakdowns for Syros Pharmaceuticals (SYRS)
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital Syros Pharmaceuticals|SYRS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital syros.com|SYRS - Company Aggregate Debts|Debt to Book Capitalization Ratio Syros Pharmaceuticals|SYRS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Syros Pharmaceuticals|Quick Ratio syros.com
- financial results and valuation multiples details:
SYRS - Net Profit|Projected Future Earnings Syros Pharmaceuticals|SYRS - Price to Earnings Ratio|Forward P/E Multiple Syros Pharmaceuticals Inc.|SYRS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Syros|SYRS - Operating profit EBITDA|Net earnings per share for the last 12 months Syros Pharmaceuticals|SYRS - Earnings per share for the last four quarters|Quarterly EPS earnings growth syros.com|SYRS - Expected net earnings per share growth this year|Earnings growth forecast for next year Syros Pharmaceuticals
- sales volume and revenue information:
Comprehensive company analysis:SYRS Syros
Adherence to biomedical research ethical standards and the environmental safety of Syros Pharmaceuticals (SYRS) laboratories establish the foundation for long-term business sustainability. This stability correlates with the forward P/E, which determines the cost per unit of expected earnings, allowing investors to assess the premium paid for future success by analyzing the issuer's forward P/E for potential market overvaluation of the asset.
Direct competitors
Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Biotechnology Inc (NAUT)|Projected Price to Earnings MGX|DTIL (Precision BioSciences) - Market Cap to Future Earnings Ratio|Future Price to Earnings Generation Bio Corp (GBIO)|Boundless Bio - Price to Future Earnings Ratio|Future Price to Earnings Exicure, Inc. XCUR|Future Price to Earnings Multiple IMNN|PHIO - Future Price to Earnings|Market Cap to Projected Earnings Mustang Bio Inc MBIO|RNAZ: Forward P/E Multiple|Price to Future Earnings Ratio BNGO|APDN (Applied DNA Sciences Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Bluebird Bio BLUE|Forward P/E Multiple IPA|Omega Therapeutics (OMGA) - Forward Price to Earnings Multiple|Forward P/E Multiple OMIC (Singular Genomics Systems Inc)|Forward Price to Earnings Multiple Regulus Therapeutics Inc|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple
